Literature DB >> 1151647

Bioavailability of micronized griseofulvin from corn oil-in-water emulsion, aqueous suspension, and commercial tablet dosage forms in humans.

T R Bates, J A Sequeria.   

Abstract

The purposes of this investigation were to determine and to compare the oral absorption characteristics of micronized griseofulvin (500 mg) after its administration to humans in the form of a corn oil-in-water emulsion containing dispersed drug, an aqueous suspension, and two different commercial tablets (A and B). The four dosage forms were administered in a random crossover fashion to five fasting subjects, and drug absorption was assessed from urinary excretion data for the major metabolite of the antibiotic (6-desmethylgriseofulvin). The drug was most rapidly, uniformly, and completely absorbed from the corn oil-in-water emulsion. As compared to either the aqueous suspension, Tablet A, or Tablet B, three- to fourfold increases in the maximum body levels and a twofold enhancement in the bioavailability of the antibiotic were observed after administration of the emulsion dosage form. A mechanism based on the ability of the linoleic and oleic acids liberated during the digestion of corn oil to inhibit GI motility and stimulate gallbladder evacuation may explain the marked enhancing effect of emulsified corn oil on griseofulvin absorption in humans. This new lipid-in-water emulsion dosage form of micronized griseofulvin appears to offer several clinical advantages in the treatment of fungal infections.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1151647     DOI: 10.1002/jps.2600640513

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  9 in total

1.  In vitro and in vivo evaluation of amorphous solid dispersions generated by different bench-scale processes, using griseofulvin as a model compound.

Authors:  Po-Chang Chiang; Yong Cui; Yingqing Ran; Joe Lubach; Kang-Jye Chou; Linda Bao; Wei Jia; Hank La; Jonathan Hau; Amy Sambrone; Ann Qin; Yuzhong Deng; Harvey Wong
Journal:  AAPS J       Date:  2013-03-02       Impact factor: 4.009

2.  Influence of bile salts and lipids on intestinal absorption of griseofulvin in man.

Authors:  R Palma; N Vidon; G Houin; A Pfeiffer; M Rongier; J Barre; J J Bernier
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

3.  In vivo model for ciclosporin intestinal absorption in lipid vehicles.

Authors:  J P Reymond; H Sucker; J Vonderscher
Journal:  Pharm Res       Date:  1988-10       Impact factor: 4.200

4.  Examination of some factors responsible for a food-induced increase in absorption of atovaquone.

Authors:  P E Rolan; A J Mercer; B C Weatherley; T Holdich; H Meire; R W Peck; G Ridout; J Posner
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

5.  Clinical studies with oral lipid based formulations of poorly soluble compounds.

Authors:  Dimitrios G Fatouros; Ditte M Karpf; Flemming S Nielsen; Anette Mullertz
Journal:  Ther Clin Risk Manag       Date:  2007-08       Impact factor: 2.423

6.  Lipid-based formulations for danazol containing a digestible surfactant, Labrafil M2125CS: in vivo bioavailability and dynamic in vitro lipolysis.

Authors:  Anne Larsen; René Holm; Mette Lund Pedersen; Anette Müllertz
Journal:  Pharm Res       Date:  2008-07-01       Impact factor: 4.200

7.  Drug solubilization behavior during in vitro digestion of suspension formulations of poorly water-soluble drugs in triglyceride lipids.

Authors:  Ann Marie Kaukonen; Ben J Boyd; William N Charman; Christopher J H Porter
Journal:  Pharm Res       Date:  2004-02       Impact factor: 4.200

8.  In situ intestinal absorption of a poorly water-soluble drug from mixed micellar solutions of bile salt and lipolysis products in rats.

Authors:  A T Serajuddin; M Rosoff; A H Goldberg
Journal:  Pharm Res       Date:  1985-09       Impact factor: 4.200

9.  In Vitro Skin Delivery of Griseofulvin by Layer-by-Layer Nanocoated Emulsions Stabilized by Whey Protein and Polysaccharides.

Authors:  Daniel P Otto; Anja Otto; Melgardt M de Villiers
Journal:  Pharmaceutics       Date:  2022-03-02       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.